ThermoDox® Phase III OPTIMA Study Fully Enrolled in August; First Pre-Planned Efficacy Analysis Expected in Mid-2019 GEN-1 Phase I/II OVATION 2 Study Enrolling Patients; First Look at Phase I Data Expected in First Quarter 2019 Company to Hold Conference Call on Thursday, November 15, 2018 at 11:00

LAWRENCEVILLE, N.J , Nov. 08, 2018 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN) announced today that the Company will host a conference call to discuss financial results for the quarter ended September 30, 2018 and provide an update on its development programs for ThermoDox®, its

  Single Arm Study Demonstrated a Median Progression-Free Survival (PFS) of 24.3 Months for Patients Treated per Protocol;  Patients in the Intent-to-Treat Population had a Median PFS of 17.1 months versus Historical Median PFS of 12 Months All Patients Treated at the Highest Dose Cohort Achieved

  Analysis in peer-reviewed journal, Future Oncology, outlines the ability of GEN-1, a non-viral nanoparticle delivery system, to support persistent local production of IL-12 LAWRENCEVILLE, N.J , Oct. 22, 2018 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), an oncology drug development

LAWRENCEVILLE, N.J. , Oct. 03, 2018 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced that on September 28, 2018 , the Compensation Committee of the Company's Board of Directors approved the grant of (i) inducement stock options (the

  Lambertson brings executive experience to the newly created position,  reinforcing Celsion’s commitment to its strategic communications and investor relations objectives LAWRENCEVILLE, N.J. , Sept. 17, 2018 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), an oncology drug development

OVATION II Study Will Evaluate Initial and Maintenance Dosing of GEN-1 on Progression-Free Survival in a Two-Arm, Randomized Trial of Up to 130 Patients LAWRENCEVILLE, N.J. , Sept. 06, 2018 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced

  550 Patient Study Designed to Determine if ThermoDox® Can Significantly Prolong the Lives of Patients with Liver Cancer OPTIMA Study’s Hypothesis Independently Confirmed by the National Institutes of Health LAWRENCEVILLE, NJ , Sept. 05, 2018 (GLOBE NEWSWIRE) -- Celsion Corporation  (NASDAQ:

  Funding Through the New Jersey Technology Business Tax Certificate Transfer (NOL) Program LAWRENCEVILLE, N.J. , Sept. 04, 2018 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced it has received approval from the New Jersey Economic

  Strong Balance Sheet With Cash Sufficient to Fund Operations Into the First Half of 2020 Quarterly and Year-to-Date Cash Expenses Consistent With Prior Guidance                Company to Hold Conference Call on Tuesday, August 14, 2018 at 11:00 a.m. EDT LAWRENCEVILLE, N.J. , Aug.